Buy the rumor, sell the (good?) news.
BriaCell's Lead Candidate Combined With KEYTRUDA(R): Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
The headline is clearly positive. The text seems more mixed. But these patients had already proven difficult to treat:
-- All 6 patients were very heavily pre-treated with a median of 5 prior
systemic therapy regimens (such as chemotherapy) prior to enrollment in
BriaCell's Combination Study.
-- These patients previously did not respond to a number of currently
available therapies outside of BriaCell, and most had very weak immune
systems, further emphasizing the importance of the positive results
observed in BriaCell's Combination Study.